Diclegis® is specifically designed to manage morning sickness symptoms all day long
Diclegis® is specifically designed to manage morning sickness symptoms- even when they last beyond the morning.
Diclegis® has a delayed-release coating designed to allow doxylamine and pyridoxine to reach peak concentrations 5-7 hours after administration. The terminal elimination half-life of doxylamine and pyridoxine are 12.5 hours and 0.5 hours, respectively. Thus, the pharmacokinetics of Diclegis® allow for sustained levels of doxylamine and pyridoxine in order to control NVP symptoms.
A food-effect study demonstrated that the delay in the onset of action of Diclegis® may be further delayed, and a reduction in absorption may occur when tablets are taken with food. Therefore, Diclegis® should be taken on an empty stomach with a glass of water.
Give your patients the proven morning sickness treatment they deserve.
Diclegis® is a fixed-dose combination drug product of doxylamine succinate, an antihistamine, and pyridoxine hydrochloride, a vitamin B6 analog, indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
LIMITATIONS OF USE
Diclegis® has not been studied in women with hyperemesis gravidarum.
IMPORTANT SAFETY INFORMATION
Diclegis® is contraindicated in women with known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride, or any inactive ingredient in the formulation. Diclegis® is also contraindicated in combination with monoamine oxidase inhibitors (MAOIs) as MAOIs intensify and prolong the adverse CNS effects of Diclegis®. Use of MAOIs may also prolong and intensify the anticholinergic (drying) effects of antihistamines.
Diclegis® may cause somnolence due to the anticholinergic properties of doxylamine succinate, an antihistamine. Women should avoid engaging in activities requiring complete mental alertness, such as driving or operating heavy machinery, while using Diclegis® until cleared to do so by their healthcare provider.
Use of Diclegis® is not recommended if a woman is concurrently using CNS depressants, such as alcohol or sedating medications, including other antihistamines (present in some cough and cold medications), opiates, and sleep aids. The combination of Diclegis® and CNS depressants could result in severe drowsiness leading to falls or other accidents.
Diclegis® has anticholinergic properties and should be used with caution in women who have: (1) asthma, (2) increased intraocular pressure, (3) an eye problem called narrow angle glaucoma, (4) a stomach problem called stenosing peptic ulcer, (5) pyloroduodenal obstruction, or (6) a urinary bladder problem called bladder-neck obstruction.
Fatalities have been reported from doxylamine overdose in children. Children appear to be at a high risk for cardiorespiratory arrest. However, the safety and effectiveness of Diclegis® in children under 18 years of age have not been established.
Diclegis® is a delayed-release formulation; therefore, signs and symptoms of intoxication may not be apparent immediately. Signs and symptoms of overdose may include restlessness, dryness of mouth, dilated pupils, sleepiness, vertigo, mental confusion, and tachycardia. If you suspect an overdose or seek additional overdose information, you can contact a poison control center at 1-800-222-1222.
Diclegis® is intended for use in pregnant women.
Women should not breast-feed while using Diclegis® because the antihistamine component (doxylamine succinate) in Diclegis® can pass into breast milk. Excitement, irritability, and sedation have been reported in nursing infants presumably exposed to doxylamine succinate through breast milk. Infants with apnea or other respiratory syndromes may be particularly vulnerable to the sedative effects of Diclegis® resulting in worsening of their apnea or respiratory conditions.